Altshuler Shaham Ltd Purchases Shares of 163,200 Haleon plc (NYSE:HLN)

Altshuler Shaham Ltd purchased a new stake in Haleon plc (NYSE:HLN - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 163,200 shares of the company's stock, valued at approximately $1,348,000.

Other large investors have also recently modified their holdings of the company. Frank Rimerman Advisors LLC purchased a new stake in Haleon during the second quarter worth $314,000. Profund Advisors LLC lifted its holdings in Haleon by 3.0% during the second quarter. Profund Advisors LLC now owns 53,889 shares of the company's stock worth $445,000 after buying an additional 1,563 shares during the period. Sei Investments Co. lifted its holdings in Haleon by 2.7% during the second quarter. Sei Investments Co. now owns 802,507 shares of the company's stock worth $6,629,000 after buying an additional 21,418 shares during the period. AE Wealth Management LLC lifted its holdings in Haleon by 6.1% during the second quarter. AE Wealth Management LLC now owns 19,199 shares of the company's stock worth $159,000 after buying an additional 1,098 shares during the period. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in Haleon by 16.6% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 49,385 shares of the company's stock worth $408,000 after buying an additional 7,026 shares during the period. Hedge funds and other institutional investors own 6.67% of the company's stock.

Haleon Stock Up 1.0 %

Shares of HLN stock traded up $0.11 during trading hours on Monday, reaching $10.63. 3,565,845 shares of the company's stock were exchanged, compared to its average volume of 4,934,885. The stock's 50 day moving average is $9.76 and its 200-day moving average is $8.88. The company has a market cap of $48.54 billion, a price-to-earnings ratio of 35.07, a P/E/G ratio of 3.10 and a beta of 0.26. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $10.76.

Haleon (NYSE:HLN - Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The business had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same period in the previous year, the company posted $0.08 earnings per share. Analysts predict that Haleon plc will post 0.46 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Investors of record on Friday, August 16th were given a $0.0514 dividend. This represents a dividend yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon's payout ratio is 33.33%.

Wall Street Analysts Forecast Growth

HLN has been the subject of a number of analyst reports. Morgan Stanley upped their target price on Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a report on Friday. Berenberg Bank initiated coverage on Haleon in a report on Tuesday, August 6th. They set a "buy" rating for the company. Finally, The Goldman Sachs Group downgraded Haleon from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Haleon currently has a consensus rating of "Moderate Buy" and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.